Article
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Oncology reports - 1 Aug 2013
Trigka Eleni Andriana, Levidou Georgia, Saetta Angelica A, Chatziandreou Ilenia, Tomos Periklis, Thalassinos Nikolaos, Anastasiou Nikolaos, Spartalis Eleftherios, Kavantzas Nikolaos, Patsouris Efstratios, Korkolopoulou Penelope
Abstract excerpt
The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog (AKT)/mammalian target of rapamycin (mTOR) pathway is upregulated in a number of human cancers, including non-small cell lung cancer (NSCLC). Its potential role in NSCLC progression provides an attractive target for anticancer therapy. The expression of phosphorylated mTOR (p-mTOR), phosphorylated AKT (p-AKT), p85α and p110γ subunits...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.